TCI Wealth Advisors Inc. Sells 347 Shares of Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on May 6th, 2023

TCI Wealth Advisors Inc. decreased its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,710 shares of the company’s stock after selling 347 shares during the quarter. Johnson & Johnson comprises 1.0% of TCI Wealth Advisors Inc.’s holdings, making the stock its 17th largest holding. TCI Wealth Advisors Inc.’s holdings in Johnson & Johnson were worth $7,015,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. Lincoln Capital Corp grew its holdings in Johnson & Johnson by 15.9% during the third quarter. Lincoln Capital Corp now owns 1,332 shares of the company’s stock worth $218,000 after buying an additional 183 shares in the last quarter. Ieq Capital LLC boosted its position in Johnson & Johnson by 5.1% in the third quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock worth $20,912,000 after purchasing an additional 6,154 shares during the last quarter. RFG Advisory LLC boosted its position in Johnson & Johnson by 2.7% in the third quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock worth $3,900,000 after purchasing an additional 594 shares during the last quarter. Willis Investment Counsel boosted its position in Johnson & Johnson by 0.4% in the fourth quarter. Willis Investment Counsel now owns 328,884 shares of the company’s stock worth $58,097,000 after purchasing an additional 1,358 shares during the last quarter. Finally, Wambolt & Associates LLC boosted its position in Johnson & Johnson by 2.5% in the fourth quarter. Wambolt & Associates LLC now owns 14,528 shares of the company’s stock worth $2,566,000 after purchasing an additional 355 shares during the last quarter. Institutional investors own 67.94% of the company’s stock.

Insiders Place Their Bets

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the sale, the insider now owns 9,215 shares in the company, valued at approximately $1,425,191.90. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.20% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $162.68 on Friday. The firm has a market capitalization of $422.76 billion, a P/E ratio of 34.03, a P/E/G ratio of 2.78 and a beta of 0.53. The company has a quick ratio of 0.77, a current ratio of 1.07 and a debt-to-equity ratio of 0.49. The stock’s 50-day simple moving average is $158.33 and its two-hundred day simple moving average is $166.96. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $183.35.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, beating the consensus estimate of $2.51 by $0.17. The firm had revenue of $24.75 billion for the quarter, compared to analyst estimates of $23.61 billion. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The company’s revenue was up 5.6% on a year-over-year basis. During the same period in the prior year, the company earned $2.67 EPS. As a group, equities analysts anticipate that Johnson & Johnson will post 10.66 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be issued a dividend of $1.19 per share. The ex-dividend date of this dividend is Monday, May 22nd. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 annualized dividend and a yield of 2.93%. Johnson & Johnson’s dividend payout ratio is currently 94.56%.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on JNJ shares. StockNews.com started coverage on Johnson & Johnson in a research report on Thursday, March 16th. They issued a “strong-buy” rating on the stock. Credit Suisse Group boosted their price objective on Johnson & Johnson from $168.00 to $170.00 in a research report on Friday. Raymond James dropped their price target on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 19th. Atlantic Securities dropped their price target on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 19th. Finally, UBS Group started coverage on Johnson & Johnson in a research report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price target on the stock. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $173.00.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.